Terumo (STU:TUO) Cyclically Adjusted Revenue per Share: €2.99 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TUO Terumo Corp STU:TUO
82 GF Score
Price €13.87
GF Value €16.90
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Terumo Cyclically Adjusted Revenue per Share?

Terumo STU:TUO -2.74% 82 Cyclically Adjusted Revenue per Share is €2.99 as of Jun. 2026. GuruFocus rates STU:TUO with a GF Score™ of 82/100 and a GF Value™ of €16.90 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Terumo's adjusted revenue per share for the three months ended in Jun. 2026 was €1.141. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.99 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Terumo's average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Terumo was 10.40% per year. The lowest was 6.20% per year. And the median was 7.30% per year.

As of today (2026-08-18), Terumo's current stock price is €13.865. Terumo's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €2.99. Terumo's Cyclically Adjusted PS Ratio of today is 4.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Terumo was 7.83. The lowest was 3.51. And the median was 5.34.


Terumo  (STU:TUO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Terumo's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.865/2.99
=4.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Terumo was 7.83. The lowest was 3.51. And the median was 5.34.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Terumo Cyclically Adjusted Revenue per Share Related Terms


Terumo Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Terumo's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Terumo Cyclically Adjusted Revenue per Share Chart

Terumo Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.71 2.82 2.76 3.07 3.03

Terumo Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 2.97 2.88 3.03 2.99

STU:TUO vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Terumo's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terumo Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Terumo's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Terumo's Cyclically Adjusted PS Ratio falls into.


STU:TUO
82GF Score
Terumo Corp STU:TUO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Terumo Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Terumo's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.141/113.6000*113.6000
=1.141

Current CPI (Jun. 2026) = 113.6000.

Terumo Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.678 98.000 0.786
201612 0.679 98.400 0.784
201703 0.760 98.100 0.880
201706 0.739 98.500 0.852
201709 0.728 98.800 0.837
201712 0.754 99.400 0.862
201803 0.762 99.200 0.873
201806 0.733 99.200 0.839
201809 0.714 99.900 0.812
201812 0.821 99.700 0.935
201903 0.820 99.700 0.934
201906 0.826 99.800 0.940
201909 0.862 100.100 0.978
201912 0.887 100.500 1.003
202003 0.882 100.300 0.999
202006 0.716 99.900 0.814
202009 0.807 99.900 0.918
202012 0.865 99.300 0.990
202103 0.844 99.900 0.960
202106 0.855 99.500 0.976
202109 0.882 100.100 1.001
202112 0.919 100.100 1.043
202203 0.910 101.100 1.023
202206 0.921 101.800 1.028
202209 0.962 103.100 1.060
202212 1.005 104.100 1.097
202303 0.948 104.400 1.032
202306 0.943 105.200 1.018
202309 0.972 106.200 1.040
202312 1.023 106.800 1.088
202403 0.988 107.200 1.047
202406 1.023 108.200 1.074
202409 1.063 108.900 1.109
202412 1.104 110.700 1.133
202503 1.106 111.100 1.131
202506 1.057 111.700 1.075
202509 1.074 112.000 1.089
202512 1.102 113.000 1.108
202603 1.110 112.700 1.119
202606 1.141 113.600 1.141

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.99 mean?
Terumo (STU:TUO) has a Cyclically Adjusted Revenue per Share of €2.99 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Terumo and its competitors.
Is Terumo's Cyclically Adjusted Revenue per Share too high?
Terumo's current Cyclically Adjusted Revenue per Share is €2.99. Overall, Terumo has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Terumo's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Terumo's Cyclically Adjusted Revenue per Share of €2.99 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Terumo and its competitors. Terumo's current Cyclically Adjusted Revenue per Share is €2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Terumo stock overvalued right now?
Based on GuruFocus' analysis, Terumo (STU:TUO) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.90, compared to a current price of €13.87 — trading 18% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.99. Terumo's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Terumo (STU:TUO), the current Cyclically Adjusted Revenue per Share is €2.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Terumo (STU:TUO) Overvalued in 2026?

Based on GuruFocus' analysis, Terumo stock appears to be undervalued. The current stock price of €13.87 is trading 18% below its estimated GF Value™ of €16.90. GuruFocus considers Terumo to be Modestly Undervalued.

Key valuation signals for STU:TUO:

  • Cyclically Adjusted Revenue per Share: €2.99
  • GF Value™: €16.90 vs. price of €13.87 (18% below fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the STU:TUO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Terumo Business Description

Address 2-44-1 Hatagaya, Shibuya-ku, Tokyo, JPN, 151-0072
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo's revenue.
82GF Score

Get the complete analysis for STU:TUO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.87
Price
€16.90
GF Value